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Abstract
We consider a new Bayesian approach for heterogeneity that can take into account categorical
covariates, if available. We use the Genetic Analysis Workshop 14 simulated data to first compare
the Bayesian approach with the heterogeneity LOD, when no covariate information is used. We
find that the former is more powerful, while the two approaches have comparable false-positive
rates. We then include informative covariates in the Bayesian approach and find that it tends to give
more precise interval estimates of the disease gene location than when covariates are not included.
We had knowledge of the simulation models at the time we performed the analyses.
Background
One of the major difficulties in mapping genes that influ-
ence complex traits is locus heterogeneity. A widely used
statistic for dealing with locus heterogeneity in linkage
analysis is the Heterogeneity LOD (HLOD) score [1].
Recently, Biswas and Lin [2] have proposed a Bayesian
approach that accounts for variable levels of heterogeneity
across different families by letting each family have its
own heterogeneity parameter. This parameter denotes the
probability that the family is of the linked type. It was
shown through simulations that this approach is more
powerful than the HLOD while the two approaches have
comparable false-positive rates.
In the current study, we first used the simulated data of the
AI population to compare the power and false-positive
rates between the Bayesian approach and the HLOD. Then
we investigated the performance of a new extension of the
Bayesian approach that incorporates informative categor-
ical covariates. We did this by applying the approach to
the all-population-combined data using the population
indicator as a covariate.
Methods
Bayesian approach
This approach is described and investigated in detail by
Biswas and Lin [2]. Briefly, suppose there are k families in
the sample. Let αj be the probability that the jth family is of
the linked type, j = 1, ..., k, and let d be the position of the
disease gene on the chromosome. Here α = (α1, ..., αk) is
a set of nuisance parameters while d is the main parameter
of interest. The likelihood of (α, d) is expressed in terms
of mixture distributions, similar to that described in [1].
Suppose there are N distances (locations) on the chromo-
some, labelled as 1, ..., N, at which the LOD scores are cal-
culated. Let Id denote the index of distance d. Then Id ∈ {1,
...., N}. The prior distribution for d consists of two com-
ponents: πd < ∞ and πd = ∞ for linkage and no linkage, respec-
tively, on the chromosome of interest. Further, for d < ∞,
there is a probability distribution of d at the N distances
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denoted by πd (Id). Let the prior distribution of αj (j = 1, ...,
k) be πj(αj).
The goal is to obtain the posterior distributions of αj val-
ues and d. The values of d < ∞ (linked subspace) and d =
∞ (unlinked subspace) lead to two different models with
a different number of parameters. The linked subspace (L)
consists of k+1 parameters (α, d) while the unlinked sub-
space (U) has no parameters, since d = ∞ renders the α
parameters meaningless. To allow moves between these
two subspaces, we use the reversible jump Markov chain
Monte Carlo sampler [3].
The Markov chain is run initially for a burn-in period of B
iterations and then for another T iterations for estimating
the posterior distributions. From the estimated posterior
distribution of d, we obtain the posterior probability of
linkage,  , which is the proportion of times the chain is
in the L subspace. If   is greater than a certain threshold,
po, we take it as a signal for linkage. In that case, an estima-
tor of the location of the disease gene under linkage is the
mean,  , of the estimated posterior distribution of d
when the chain is in the L subspace. An interval estimate
is obtained by computing a Bayesian credible set (CS) for
d under linkage.
We use the following prior distributions: πj(αj) is U(0,1),
j = 1, ...,k, πd< ∞ = 1/10 (the probability that a randomly
chosen chromosome of the simulated data will harbor the
disease gene), πd = ∞ = 9/10, and πd (Id) = 1/N, Id = 1, ..., N.
We let B = 10,000, T = 300,000, following Biswas and Lin
[2]. In their study, the values of πd< ∞ and threshold, po,
were, respectively, 1/22 and 0.5 (Bayes rule for the 0–1
loss function), which in turn corresponded to a Bayes fac-
tor of 21. Because we are using a different πd< ∞, the Bayes
factor of 21 is obtained when po = 0.7 and so we use this
threshold in our analyses.
Incorporating categorical covariates
One way of incorporating categorical covariates is using a
hierarchical model in which the α parameters have pre-
specified hyper-priors. We describe one implementation
of this idea as follows: suppose there are G groups of fam-
ilies in the sample corresponding to G categories of cov-
ariate(s). These G  categories may be G  levels of one
covariate or G combinations of levels of two or more cov-
ariates. Suppose the ith group has ni families, i = 1, ..., G.
Denote the α parameter of the jth family in the ith group by
αij, j = 1, ..., ni, i = 1, ..., G. Assume that the prior distribu-
tion of αij, πij(αij), is Beta(ai + 1,   - ai + 1) with
hyper-parameter  ai  following  Binomial(,   φi).
Here, ti, for 0 <ti ≤ 1, is a tuning parameter needed only for
computational purposes (explained below). The value of
φi is prespecified according to the covariate value in the ith
category. If the ith group is likely to have more linked fam-
ilies, it is assigned a higher value of φi. The ti values may be
set to 1. However, large ni values lead to large parameters
for Beta distributions, which make them highly concen-
trated in a narrow range. This can dramatically increase
the computation time for updating the αij values for some
families when using rejection sampling. We use ti = 0.1 for
all i.
Results
We used the following genetic model, where D denotes
the disease allele: P(D) = 0.2, and penetrances for geno-
types dd, Dd, and DD are 0.05, 0.5, and 0.7, respectively.
This is a kind of incomplete penetrance model that one
might use as an approximation to the true but unknown
complex model. The data used are microsatellite markers
and affection statuses. We used GENEHUNTER version
2.1_r5 beta [4] to compute multipoint LOD and HLOD
scores at every 1 cM, starting from 10 cM above the first
marker and ending at 10 cM beyond the last marker on a
chromosome. We let the GENEHUNTER (with its max
bits option set to 18) drop any members automatically in
its computations.
Comparison of Bayesian approach with HLOD
We analyzed all 100 replicates and all ten chromosomes
for population AI. The number of replicates that give a
linkage signal at any location on each chromosome using
the Bayesian approach and HLOD are shown in Table 1.
For HLOD, a cut-off of 3.7 is used to declare linkage, fol-
lowing the recommendation of Greenberg and Abreu [5]
for multipoint analysis. According to the simulation
model, there are four disease loci, one each on chromo-
somes 1, 3, 5, and 9, while there are two modifying loci,
one each on chromosomes 2 and 10. Table 1 shows that
the Bayesian approach is more powerful than the HLOD.
The Bayesian approach (with a threshold of 0.7) gives one
false positive while the HLOD gives zero false positives.
Although this false-positive rate for the Bayesian approach
is very low (1/400 = 0.0025) in the absolute sense, we also
explored increasing its cut-off, po, to 0.73 (results also
shown in Table 1) so that its false-positive rate becomes
zero; we see that the Bayesian approach retains higher
powers than the HLOD. We also note that all 95% CSs for
the Bayesian approach (results not shown) contain their
corresponding disease gene locations when linkage is
detected on chromosomes 1, 5, 9, and 10. This result can-
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"answers" provided for the simulation model only indi-
cated that the disease gene on this chromosome lies
beyond the last SNP marker, and hence its exact location
is unknown to us.
Analysis with covariate
We used the population indicator (which takes the values
AI, KA, DA, or NYC) as a covariate. These populations dif-
fer in the diagnostic schemes used, which are based on
three broad categories of symptoms: communally-shared
emotions (COM), behavioral (BEH), and anxiety-related
(ANX). In AI and NYC, a person is considered to be
affected by Kofendrerd Personality Disorder if he/she has
any of the three types of symptoms. In KA, the criterion is
the presence of COM or ANX, while in DA only BEH mat-
ters. NYC consists of extended pedigrees in contrast to the
other three populations that comprise nuclear families
only. Furthermore, NYC differs from the others in its
ascertainment scheme. The varying diagnostic and ascer-
tainment schemes can be expected to give rise to some
heterogeneity across populations. Specifically, if there is a
locus that influences COM and/or ANX but not BEH, then
DA is not expected to contain information about this
locus while KA is the most homogeneous and hence most
informative for detecting the locus. On the other hand,
DA is most informative for a locus influencing BEH. Also,
although both AI and NYC are phenotypically heteroge-
neous, NYC families may contain more linkage informa-
tion because the families ascertained are extended
pedigrees with at least four affected members.
In our first analysis, we found linkage signals on chromo-
somes 1, 3, 5, and 9 in numerous replicates. Although we
used population AI only, all three types of symptoms (and
hence all loci influencing them) are present in the AI fam-
ilies, thus we decided to focus on these chromosomes
only. Following the above reasoning concerning the
informativeness of populations for different types of loci,
we considered two possible sets of binomial parameters
(φi) for (AI, KA, DA, NYC): 1) (0.5, 0.4, 0.9, 0.6) and 2)
(0.5, 0.9, 0.2, 0.6). We analyzed the first 25 replicates with
both sets of covariate settings and without covariate. The
results for the first 5 replicates only are shown in Table 2;
those for the other 20 replicates are similar and thus are
omitted from the table. For the results with covariate, we
have listed the results for the set of φi parameters that gave
a higher posterior probability of linkage (set 1 for chro-
mosomes 1 and 3; set 2 for chromosomes 5 and 9).
From Table 2, we see that for most of the chromosome 1,
5, and 9 replicates, including covariate information leads
to narrower interval estimates (CSs). This observation also
holds true for all 25 replicates that we analyzed. More spe-
cifically, with covariate information, the proportions that
have narrower CSs are 0.8, 0.5, and 0.6 for chromosomes
1, 5, and 9, respectively, whereas without covariate infor-
mation, the corresponding proportions are only 0.12,
0.23, and 0.2. However, for chromosome 3, it appears that
including the covariate is not useful and may even lead to
some loss of power (see below).
Conclusion
Our study shows that the Bayesian approach is more pow-
erful than the HLOD while the two have comparable
false-positive rates, consistent with Biswas and Lin [2].
From Table 1, we observe that the relative power gains for
detecting the disease loci using the Bayesian approach
(with a cut-off of 0.73) compared to the HLOD range
from 35% to 100%, a finding also similar to that in Biswas
and Lin [2]. This is noteworthy because, unlike their sim-
ulation models, all the underlying disease models of the
GAW14 data are epistatic and do not follow a heterogene-
ity model. This shows that our Bayesian approach per-
forms better than the HLOD under more complicated
disease models also. We note that there is another Baye-
sian approach for mapping under heterogeneity [6],
although it differs from the approach we propose in many
significant aspects, including its basic formulation.
Table 1: Numbers of replicates (out of 100 for each chromosome) that give linkage signals for population AI.
Chromosome
1a 2b 3a 45 a 6789 a 10b
Bayesian (  > 0.7)
3 003 102 10 0 11 01
Bayesian (  > 0.73)
2 703 101 90 0 01 01
H L O D  ( H L O D  >  3 . 7 ) 2 0 0 2 3 0 1 0 00050
aChromosome harbors the disease gene.
bChromosome harbors the modifying loci.
ˆ p
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According to the simulation model, the disease gene on
chromosome 1 (D1) influences BEH strongly and either
ANX or COM moderately, with no effect on the other type
of symptom. The genes on chromosomes 5 (D3) and 9
(D4) influence COM and ANX only while the one on
chromosome 3 (D2) affects all symptoms, with a slightly
stronger effect on BEH. Our results are consistent with this
simulation model, since of the two sets of φi values, we
expect, the first set to target D1 and the second set to point
toward D3 and D4. This illustrates how prior information
(in this case the diagnostic and ascertainment schemes)
can be used to form informative covariates that refine the
linkage analysis by yielding narrower CSs and even uncov-
ering signals for linkage that might otherwise be missed.
H o w e v e r ,  w e  n o t e  t h a t  e v e n  w h e n  n o  c o v a r i a t e  i s
included, the linkage signals in most of the replicates with
all populations combined are so strong (indicated by   ≈
1 in Table 2) that little room is left for further improve-
ment when a covariate is included. This is the most likely
reason why including the covariate led to only minor
ˆ p
Table 2: Bayesian approach resultsa with (Y) or without (N) "population" covariate.
Replicate 
Number
Covariate Chromosome 1 Chromosome 3
95% CS 95% CS
1 Y 1.000 166.70 (163, 171) 1.000 297.99 (294, 304)
N 1.000 166.68 (163, 172) 1.000 297.32 (294, 302)
2 Y 0.983 172.43 (165, 178) 0.696 - -
N 0.947 171.41 (161, 178) 0.787 299.07 (291, 306)
3 Y 1.000 169.67 (165, 175) 0.993 298.92 (292, 306)
N 1.000 169.86 (165, 176) 0.994 297.60 (292, 306)
4 Y 1.000 164.30 (161, 169) 0.999 300.12 (294, 306)
N 1.000 164.22 (159, 170) 0.999 298.90 (293, 306)
5 Y 1.000 169.21 (166, 173) 1.000 296.91 (294, 301)
N 1.000 168.71 (165, 173) 1.000 296.82 (294, 300)
Chromosome 5 Chromosome 9
95% CS 95% CS
1 Y 0.996 0.00 (0, 5) 0.998 1.76 (0, 10)
N 0.971 0.00 (0, 6) 0.981 2.22 (0, 12)
2 Y 1.000 8.02 (4, 12) 1.000 6.64 (0, 11)
N 1.000 8.68 (4, 13) 0.998 6.61 (0, 13)
3 Y 1.000 3.14 (0, 12) 0.735 0.00 (0, 10)
N 1.000 3.85 (0, 12) 0.172 - -
4 Y 0.108 - - 0.973 0.00 (0, 9)
N 0.297 - - 0.995 1.43 (0, 9)
5 Y 0.998 4.02 (0, 12) 0.001 - -
N 0.998 5.33 (0, 12) 0.001 - -
a  and 95% CS are the mean and (2.5th, 97.5th) percentiles of the estimated posterior distribution of d under linkage, respectively.   and CS are 
reported only if posterior probability of linkage   > 0.7. Note that the 0 in the lower limits of the CS and the   values are due to the truncations 
of negative map positions that resulted from consideration of positions 10 cM before the first marker, for computational reasons.
ˆ p ˆ m ˆ p ˆ m
ˆ p ˆ m ˆ p ˆ m
ˆ m ˆ m
ˆ p ˆ mPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genetics 2005, 6:S138
Page 5 of 5
(page number not for citation purposes)
reductions in the widths of CSs (mostly 1 cM). Neverthe-
less, since this reduction is consistently seen across the
majority of the 25 samples analyzed, it appears that it is
truly due to the effect of the covariate rather than random
variation. In any case, further evaluations and refinements
are needed to assess the benefits of incorporating covari-
ates. For instance, a more objective method for choosing
the φi values, such as through the use of an empirical Bayes
approach, should be explored. Such an approach may also
reveal when a covariate is not informative, as it was for the
chromosome 3 data. In this case the inclusion of the cov-
ariate should not be recommended, because otherwise it
may lead to wider CSs and even a loss of power (as in the
case of replicate 2 of chromosome 3 in Table 2).
The approximate locations of D1, D2, D3, and D4 are,
respectively, 169, 299 (location of the last SNP), 5, and 6
cM on their respective chromosomes based on the micro-
satellite map. Compared with the CSs in Table 2, we see
that all of them are able to capture their corresponding
true disease gene locations. We conclude that the Bayesian
approach is a powerful tool for localizing a disease gene
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